Ziresovir is a potent, selective, and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion (F) protein with EC50 of 3 nM and highlights pharmacokinetics in animal species.

Ziresovir is a potent, selective, and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion (F) protein with EC50 of 3 nM and highlights pharmacokinetics in animal species.

Ziresovir is a potent, selective, and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion (F) protein with EC50 of 3 nM and highlights pharmacokinetics in animal species.

Gliocidin (SW106065), is a nicotinamide-mimetic prodrug that targets glioblastoma cells with an IC50 of 150 nM, by exploiting a de novo purine synthesis vulnerability via indirect inhibition of IMPDH2. It readily crosses the BBB and can be used in the treatment of all malignant brain tumors.

Gliocidin (SW106065), is a nicotinamide-mimetic prodrug that targets glioblastoma cells with an IC50 of 150 nM, by exploiting a de novo purine synthesis vulnerability via indirect inhibition of IMPDH2. It readily crosses the BBB and can be used in the treatment of all malignant brain tumors.

Gliocidin (SW106065), is a nicotinamide-mimetic prodrug that targets glioblastoma cells with an IC50 of 150 nM, by exploiting a de novo purine synthesis vulnerability via indirect inhibition of IMPDH2. It readily crosses the BBB and can be used in the treatment of all malignant brain tumors.

Gliocidin (SW106065), is a nicotinamide-mimetic prodrug that targets glioblastoma cells with an IC50 of 150 nM, by exploiting a de novo purine synthesis vulnerability via indirect inhibition of IMPDH2. It readily crosses the BBB and can be used in the treatment of all malignant brain tumors.

SD-436 is a potent and selective PROTAC degrader of STAT3 with a DC50 of 0.5 μM. It induces complete and long-lasting tumor regression in leukemia and lymphoma xenograft models in mice.

SD-436 is a potent and selective PROTAC degrader of STAT3 with a DC50 of 0.5 μM. It induces complete and long-lasting tumor regression in leukemia and lymphoma xenograft models in mice.

SD-436 is a potent and selective PROTAC degrader of STAT3 with a DC50 of 0.5 μM. It induces complete and long-lasting tumor regression in leukemia and lymphoma xenograft models in mice.